SOX2 and liver cancer: In liver cancer cells, CAP treatment downregulated the expression of silent information regulator 1 (SIRT1), resulting in reduced SOX2 deacetylation, thereby reducing the stability of SOX2 and leading to the transfer of SOX2 from the nucleus to the cytoplasm.